Clinical research

Dr. Lyudmila Sarder Receives Rave Reviews from Lakeland Regional Health and AdventHealth Cancer Institute for Research

Retrieved on: 
Tuesday, August 22, 2023

Lakeland, FL, Aug. 21, 2023 (GLOBE NEWSWIRE) -- AdventHealth Cancer Institute proudly unveiled findings that mark a significant milestone in the cancer research field.

Key Points: 
  • Lakeland, FL, Aug. 21, 2023 (GLOBE NEWSWIRE) -- AdventHealth Cancer Institute proudly unveiled findings that mark a significant milestone in the cancer research field.
  • Meanwhile, Lakeland Regional Health takes great pride in their resident physician who played a pivotal role in the research.
  • Photo: Dr. Lyudmila Sarder, MD, Resident Physician at Lakeland Regional Health, with Dr. Luis Daniel Lugo, MD, Program Director, Internal Medicine, Lakeland Regional Health | Lakeland, Florida
    Dr. Lyudmila Sarder , a Resident Physician at Lakeland Regional Health in Florida, and Dr. Sarfraz Ahmad , who is the Director of Clinical Research at the Gynecologic Oncology Department at AdventHealth Cancer Institute, collaborated to shed light on the emerging role of biosimilars in the treatment of HER2-positive breast cancer .
  • Photo: Dr. Lyudmila Sarder, MD, Resident Physician at Lakeland Regional Health with Dr. Sarfraz Ahmad, PhD, Director of Clinical Research at the Gynecologic Oncology Department at AdventHealth Cancer Institute | Orlando, Florida
    Dr. Sarder and Dr. Ahmad's research highlights the potential of biosimilars to alleviate the financial burden faced by cancer patients.

InBody Hits Milestone: 100 Million Tests Recorded Globally on Their LookinBody Web Platform

Retrieved on: 
Thursday, August 17, 2023

Highlighting a growing interest in body composition data, InBody is celebrating a long-anticipated milestone: 100 million tests taken globally on their body composition analyzers as of Friday, Aug. 4.

Key Points: 
  • Highlighting a growing interest in body composition data, InBody is celebrating a long-anticipated milestone: 100 million tests taken globally on their body composition analyzers as of Friday, Aug. 4.
  • (Photo: Business Wire)
    “We’ve come a long way since InBody’s founding in 1996,” said Harry Yun, CEO of InBody USA.
  • “You can get an InBody Test almost anywhere in the world these days!”
    Currently, most consumers access InBody Tests through their healthcare facilities, pharmacies and gyms.
  • Many large companies also offer InBody Tests on-site as a part of their wellness programs, including several Fortune 500 corporations.

Eisai to Present the Latest Alzheimer's Disease Pipeline and Research

Retrieved on: 
Wednesday, July 12, 2023

The conference will be held in Amsterdam, the Netherlands and virtually from July 16 to 20, 2023.

Key Points: 
  • The conference will be held in Amsterdam, the Netherlands and virtually from July 16 to 20, 2023.
  • Eisai will present data and research in eight oral and 19 poster presentations at the meeting.
  • Two of the AAIC oral presentations will be presented as posters at the Alzheimer's Disease Imaging Consortium (AIC), which will be held at the same venue as AAIC on July 15.
  • "At AAIC 2023 Eisai will present the latest data on lecanemab, an anti-Aβ protofibril antibody, that recently received traditional approval in the U.S. for patients with mild cognitive impairment (MCI) due to AD and mild AD.

Javara, Nevada Health Centers Announce Partnership to Bring Clinical Research to the Geographically Isolated, Medically Underserved

Retrieved on: 
Monday, August 7, 2023

Javara , a leading integrated research organization (IRO) focused on delivering access to clinical trials at the point of care, today announced a strategic partnership with Nevada Health Centers (NVHC).

Key Points: 
  • Javara , a leading integrated research organization (IRO) focused on delivering access to clinical trials at the point of care, today announced a strategic partnership with Nevada Health Centers (NVHC).
  • “Javara is grateful for the trust of Nevada Health Centers to bring access to novel treatments and innovative health care options to these communities for the first time.
  • As the first-ever clinical research partner to join forces with an FQHC, Javara is eager to deliver Clinical Research as a Care Option to patients across Nevada.
  • “When seeking a partner to guide Nevada Health Centers’ efforts to develop a clinical trials program for our patients, Javara most closely aligned with our organizational mission and vision,” said Walter Davis, Nevada Health Centers CEO.

Optimizing Study Execution in Obesity Clinical Trials: Considerations for Recruitment and Retention, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Thursday, August 3, 2023

TORONTO, Aug. 3, 2023 /PRNewswire-PRWeb/ -- Obesity is a globally recognized health crisis. As awareness and the prevalence of this disease continue to grow, so does the urgency for effective treatment methods. Clinical trials are a crucial component of discovering and refining these interventions, but the management of obesity trials presents distinct challenges, particularly in the areas of recruitment and retention of participants.

Key Points: 
  • In this free webinar, learn the strategies for managing rapid enrollment in obesity clinical trials.
  • To address these issues and provide insights into optimizing study execution, a distinguished panel of experts from Medpace will lead an insightful webinar titled "Optimizing Study Execution in Obesity Clinical Trials: Considerations for Recruitment and Retention."
  • The session will be invaluable for professionals working within Clinical Affairs, Clinical Research, Clinical Pharmacology, Clinical Outsourcing, Clinical Operations, Regulatory Affairs and Medical Affairs.
  • Medpace and Xtalks have joined forces for this webinar to share knowledge and foster collaborative discussions.

Dr. Vince Clinical Research Joins the Fight Against the Fentanyl Crisis, Announces Screening of First Subject for Cessation Therapeutics’ Overdose Prevention Therapy in a First-In-Human Trial

Retrieved on: 
Wednesday, August 2, 2023

CSX-1004 is a human monoclonal antibody infusion that is being developed for the prevention of fentanyl overdose.

Key Points: 
  • CSX-1004 is a human monoclonal antibody infusion that is being developed for the prevention of fentanyl overdose.
  • The study is being conducted at DVCR’s world-class clinical pharmacology unit located in Overland Park, Kansas .
  • CSX-1004 potently binds to fentanyl and structurally related synthetic opioids, blocking them from entering the brain.
  • Cessation’s Chief Scientific Officer Andy Barrett, Ph.D., stated, “We are thrilled to partner with Dr. Vince Clinical Research on this critical First-In-Human study.

Affimed Announces an ASCO Breakthrough Poster Presentation with Clinical Data of AFM24 in Combination with NKGen Biotech’s SNK01 NK Cells

Retrieved on: 
Monday, July 31, 2023

The presentation includes dose escalation phase data on safety and efficacy of the phase 1 study in patients with advanced or metastatic EGFR-expressing solid tumors (NCT05099549).

Key Points: 
  • The presentation includes dose escalation phase data on safety and efficacy of the phase 1 study in patients with advanced or metastatic EGFR-expressing solid tumors (NCT05099549).
  • As of June 2023, seven patients with a mean number of five prior therapies received the combination of AFM24 and SNK01.
  • No unexpected or dose-limiting toxicities were observed, and the PK properties were similar to AFM24 monotherapy.
  • “The poster at ASCO Breakthrough is the first clinical presentation of a bispecific NK cell engager in combination with autologous NK cells,” said Dr. Anthony El-Khoueiry, Associate Director of Clinical Research and Phase I Program Director at the USC Norris Comprehensive Cancer Center and principal investigator of the AFM24 studies.

Agenus Botensilimab/Balstilimab Data Update in Sarcomas Selected for Oral Presentation at ESMO 2023

Retrieved on: 
Friday, July 28, 2023

Immuno-oncology leader, Agenus Inc. (“Agenus”) (Nasdaq: AGEN), today announced a data update from the phase 1 expansion cohort of botensilimab (multifunctional CTLA-4 antibody) in combination with balstilimab (PD-1 antibody) for patients with advanced, refractory sarcomas has been selected for an oral presentation at the upcoming ESMO Congress, to be held October 20 – 24, 2023 in Madrid, Spain.

Key Points: 
  • Immuno-oncology leader, Agenus Inc. (“Agenus”) (Nasdaq: AGEN), today announced a data update from the phase 1 expansion cohort of botensilimab (multifunctional CTLA-4 antibody) in combination with balstilimab (PD-1 antibody) for patients with advanced, refractory sarcomas has been selected for an oral presentation at the upcoming ESMO Congress, to be held October 20 – 24, 2023 in Madrid, Spain.
  • Presenting Author: Breelyn A. Wilky, MD, Director of Sarcoma Medical Oncology, Deputy Associate Director for Clinical Research, University of Colorado Cancer Center
    Data presented at the conference will be available to view in the publications section of the Agenus website ( https://agenusbio.com/publications ) following the ESMO Conference.

iuvo BioScience Hires Industry Executive to Lead Clinical Research Team

Retrieved on: 
Tuesday, July 18, 2023

ROCHESTER, N.Y., July 18, 2023 /PRNewswire-PRWeb/ -- iuvo BioScience, a specialty CRO providing laboratory services, preclinical and clinical development services, and scientific consulting services to pharmaceutical and medical device customers, today announced it has hired Lacey Powers, MSJ as its new VP, Clinical Research. This hire demonstrates iuvo's ongoing commitment to serving our clients, delivering differentiated expertise across our service offerings, and continued investment in the clinical research business to support the company's growth trajectory.

Key Points: 
  • iuvo BioScience, a specialty CRO providing laboratory services, preclinical and clinical development services, and scientific consulting services to pharmaceutical and medical device customers, today announced it has hired Lacey Powers, MSJ as its new VP, Clinical Research.
  • ROCHESTER, N.Y., July 18, 2023 /PRNewswire-PRWeb/ -- iuvo BioScience, a specialty CRO providing laboratory services, preclinical and clinical development services, and scientific consulting services to pharmaceutical and medical device customers, today announced it has hired Lacey Powers, MSJ as its new VP, Clinical Research.
  • Powers is an experienced clinical research executive who brings over twenty years of diverse experience to this role.
  • Daniel Spasic, Board Chair of iuvo BioScience, said, "We are excited to welcome Lacey to the iuvo family and our clinical development organization.

Median Technologies Announces Onboarding of All Academic Sites Involved in the Pivotal Validation Plan for iBiopsy® LCS CADe/CADx SaMD

Retrieved on: 
Monday, July 17, 2023

For the purposes of its pivotal validation plan, Median Technologies has signed clinical research agreements with world-class academic healthcare institutions, which are leading healthcare centers for the management of lung cancer patients.

Key Points: 
  • For the purposes of its pivotal validation plan, Median Technologies has signed clinical research agreements with world-class academic healthcare institutions, which are leading healthcare centers for the management of lung cancer patients.
  • Median’s pivotal validation plan is composed of a pivotal standalone performance study (MT-LCS-002) and an international Multi-Reader Multi-Case (MRMC) pivotal clinical trial (MT-LCS-004).
  • Data quality is compulsory for the proper conduct of our pivotal validation plan” said Fredrik Brag, CEO and Founder of Median Technologies.
  • Now that we have onboarded all the sites, we are on track for the launch of our iBiopsy® LCS CADe/CADx SaMD pivotal validation plan.